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Abstract Breast cancer is a major cause of cancer-related
deaths in women. It is known that obesity is one of the risk
factors of breast cancer. The subject of our interest was
genes: FTO, MC4R and NRXN3–associated with obesity. In
thisstudywehaveanalyzedfrequenciesofgenomicvariants
inFTO,MC4RandNRXN3 inthegroupof134breastcancer
patients. We genotyped two polymorphic sites located in
FTO gene (rs993909 and rs9930506), one polymorphic site
of MC4R gene (rs17782313) and one polymorphic site of
NRXN3 gene (rs10146997). Our hypothesis was that above
mentioned SNPs could participate in carcinogenesis. Our
research has showed that only rs10146997 was signiﬁcantly
(P = 0.0445) associated with higher risk of breast cancer
development (OR = 0.66 (95% CI 0.44–0.99)). Moreover,
G allele carriers in rs10146997 of the NRXN3 gene were the
youngest patients at onset of breast cancer. On the basis of
ourresearchwesuggestthatfurtherfunctionalmayelucidate
the role of genomic variation in breast cancer development.
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Introduction
Approximately 20% of deaths worldwide are due to com-
plications of the overweight and obesity which are risk
factors for type 2 diabetes and cardiovascular diseases as
well as for cancer and cancer-related mortality [1]. Since
breast cancer is one of major causes of cancer deaths in
women, the relative inﬂuence of obesity-mediated hor-
mones, proinﬂammatory mediators, and adipokines on
tumor development and progression as well as its genetic
background should be precisely assessed [2].
Increased production of estrogens in adipose tissue is
considered to be one of the most crucial mechanisms
potentially contributing to the risk of developing breast
cancer as well as to worse prognosis in obese patients [3].
In obese women, adipose tissue is an active endocrine and
metabolic tissue and produces an excess of estrogens due
to increased tissue mass and up-regulation of aromatase.
Furthermore, obesity is also associated with a lower level
of sex hormone–binding globulin that restricts the bio-
logic activity of estrogens [4]. Another factor that pro-
motes breast cancer development and progression in
patients with overweight or obesity is insulin resistance
[5]. Insulin is involved not only in growth of primary
tumor because of mitogenic, antiapoptotic, and proangi-
ogenic properties but also in progression of metastasis due
to increased level of IGF-1 [5]. Finally, in obese patients
carcinogenesis is probably modulated indirectly by adi-
pose tissue hormones such as leptin and adiponectin [6].
The ﬁrst one stimulates transcription of aromatase, which
results in increased production of estrogens. Overexpres-
sion of leptin in breast cancer is associated with the
development of metastases and shorter survival. In con-
trast, lower level of adiponectin contributes to insulin
resistance.
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the last years revealed that common low-penetrance sus-
ceptibility alleles of FTO, MC4R and NRXN3 genes are
associated with obesity in general population [7]. In the
current study we aim to explore whether the susceptibility
for breast cancer in obese woman is also partially promoted
by genomic variation at 16q12.2/FTO, 18q22/MC4R and
14q31/NRXN3 loci previously considered as obesity sus-
ceptibility regions.
Materials and methods
Patients
Specimens were consecutively obtained from 134 women
with operable invasive ductal carcinomas not otherwise
speciﬁed (NOS) at a time of routine surgery at the
Oncology Department of Copernicus Memorial Hospital in
Lodz, Poland, between 1998 and 2001. In all cases, sur-
gical procedure was a radical mastectomy with axillary
lymph node dissection. The primary pathologic diagnosis
was conﬁrmed in H&E staining.
Methods
Fresh tumor specimens were frozen immediately after
excision at -80C. All specimens were homogenized by
means TissueRuptor (Qiagen, Germany). Genomic DNA
was extracted with the QIAamp DNA Mini Kit (Qiagen,
Germany) according to the manufacturer’s instructions.
The concentrations of extracted DNAs were measured by
NanoDrop 8000 Spectrophotometer (Thermo Scientiﬁc,
USA). Each DNA sample was adjusted to 5 ng/ll con-
centration. All assayed polymorphic sites were analyzed by
TaqMan allelic discrimination assay (Applied Biosystems,
USA). All polymerase chain reactions (PCRs) were done in
a volume of 5 ll containing TaqMan universal PCR Master
Mix, speciﬁc TaqMan SNP Genotyping Assays (Applied
Biosystems, USA) and 10 ng of genomic DNA, accord-
ing to the manufacturer’s instructions. Thermal cycling
conditions were 10 min at 95C, and 42 cycles each of
95C for 15 s and 60C for 1 min. The 7900HT Real-Time
PCR System (Applied Biosystems, USA) was used for
genotyping.
Statistical analysis
Univariate comparisons were performed using Pearson’s or
Yates’ corrected v
2 test depending on number of degrees of
freedom and sample size. These tests evaluated the dif-
ferences of observed allele frequencies between the groups
in comparison to those expected purely by chance.
Distributions of alleles within controls were tested against
the Hardy–Weinberg equilibrium. This comparison evalu-
ated whether the control group is a representative sample of
the population with terms of expected allele distribution.
Continuous variables were compared using analysis of
variance or Student’s t-test depending on the number of
groups and presented as means with standard deviations
(SD)/95% conﬁdence intervals. Analysis of variance was
used when more than two groups were compared, while the
Student’s t-test compared means and SD between two
groups. Odds ratios (OR) with 95% Conﬁdence intervals
(95% CI) were calculated where possible. An effect with
OR\1 signiﬁed a protective effect, while one with an
OR[1 represented an increased likelihood of developing
cancer in individuals with a given genotype. Statistical
signiﬁcance was declared when the P value was lower than
the 0.05 threshold or the 95% CI for OR did not overlap the
value of 1 representing a neutral or ambiguous effect.
Results
Age of diagnosis and other characteristics of the study
group are listed in Table 1. The sample size consisted of
134 cases. The mean age of the group was 57.45 but twice
more women were over 50 years of age then 50 years or
younger. Less than one-third had the ﬁrst stage of disease.
Number of patients with lymph node metastases was
almost equal to the number of non-metastatic ones.
Frequencies of genotypes at respective loci are given in
Table 2. No deviations from the H–W equilibrium were
observed. The most frequent genotypes of FTO gene were
TA (65 cases) and AG (64 cases) in rs9939609 and
rs9930506 respectively. In case of rs1778231 of MC4R
Table 1 Patient characteristics Factor Number
of patients
Number of patients 134
Age (years, mean)
B57.45 74
[57.45 60
Stage
I2 7
II–IV 107
Tumor
T1 37
T2–4 97
Nodal status
Positive 70
Negative 64
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123gene and rs10146997 of NRXN3 gene there were the largest
number of homozygotes (TT and AA respectively).
Comparative analysis of genotype frequencies between
the control and breast cancer group are summarized in
Table 3. Among analyzed genotypes only the presence of G
allel in polymorphic site rs10146997 in NRXN3 was signif-
icantly (P = 0.0445) associated with higher risk of breast
cancer development [OR = 0.66 (95% CI 0.44–0.99)].
The effect of genotype on age at onset of breast cancer is
shown in Table 4. The youngest age at onset of breast
cancer had women who were G allele carriers in
rs10146997 of the NRXN3 gene, the oldest age at onset–C
allele carriage in rs177782313 of the MC4R gene, but none
of them achieved statistical signiﬁcance.
Discussion
Obesity and overweight are important risk factors for
developing a breast cancer in postmenopausal women.
Insulin resistance, chronic inﬂammation and altered adi-
pokines secretion are common phenomena in obesity and
they promote cancer progression. However, the role of
genomic variation signiﬁcantly linked with the excess of
body mass in the development of breast cancer is still
poorly understood. In the current study we analyzed the
frequency of genomic variants in FTO, MC4R and NRXN3,
previously indicated by the GWA studies as the obesity
susceptibility genes, in population of women with breast
cancer.
We genotyped two polymorphic sites located in FTO
gene (16q12.2) which encodes the protein involved in
DNA dealkylation, demethylation and repair [8]. FTO
mRNA is most abundant in the brain and pancreatic islets
[8]. Frayling et al. identiﬁed a common variant in the FTO
Table 3 Comparisons of genotype frequencies between breast cancer
patients and controls
Breast cancer vs. controls (P value)
FTO rs9939609
All genotypes 0.7739
A allele carriage 0.8368
OR 1.05 (95% CI 0.68–1.61)
FTO rs9930506
All genotypes 0.6171
G allele carriage 0.9681
OR 1.01 (95% CI 0.65–1.57)
MCR4R rs1778231
All genotypes 0.8390
C allele carriage 0.9516
OR 1.01 (95% CI 0.68–1.51)
NRXN3 rs10146997
All genotypes 0.0862
G allele carriage 0.0445
OR 0.66 (95% CI 0.44–0.99)
OR odds ratio
Table 4 Age of diagnosis of breast cancer depending on genotype
Mean SD -95.00% ?95.00% NP
FTO rs 9939609
TT 56.87500 12.39559 53.05101 60.69899 40 0.6411
TA 56.95385 12.19174 53.95406 59.95363 65
AA 59.34483 12.06315 54.85378 63.83588 29 0.7266
FTO rs9930506
AA 57.27027 12.67028 53.31707 61.22347 37 0.3019
AG 56.14063 11.88953 53.13482 59.14643 64
GG 60.18182 12.08164 55.99588 64.36776 33 0.9175
MC4R rs17782313
TT 56.07792 12.20630 53.35509 58.80076 77 0.1304
TC 58.42857 11.39444 55.01532 61.84183 49
CC 64.62500 14.89907 56.17763 73.07237 8 0.1306
NRXN3 rs10146997
AA 58.58537 12.48896 55.92941 61.24132 82 0.3090
AG 56.13333 11.82178 52.54807 59.71860 45
GG 52.57143 9.82950 43.48113 61.66173 7 0.1753
Table 2 Genotype frequencies in breast cancer and controls
Group FTO rs9939609
TT TA AA P for HWE
Controls 110 180 67 0.66
Breast cancer 40 65 29
Group FTO rs9930506
AA AG GG P for HWE
Controls 102 189 76 0.50
Breast cancer 37 64 33
Group MCR4R rs1778231
TT TC CC P for HWE
Controls 212 128 27 0.21
Breast cancer 77 49 8
Group NRXN3 rs10146997
AA AG GG P for HWE
Controls 188 145 35 0.37
Breast cancer 82 45 7
HWE Hardy–Weinberg equilibrium
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123gene as a risk factor for diabetes and obesity [9]. Almost
16% of white Europeans are homozygous for the A allele
of rs9939609 and these carriers are 1.67 times likely to be
obese in comparison with homozygous for the T allele [9].
Subsequent polymorphic site, which was taken under
consideration was rs17782313 located in MC4R gene. The
protein encoded by this gene is a member of the melano-
cortin receptor family—membrane-bound receptor which
is mediated by G proteins and interacts with adrenocorti-
cotropic and MSH hormones [10]. The correlation between
the signaling properties of these mutant receptor and
energy intake emphasizes the key role of this receptor in
the control of eating behavior in humans. Melanocortin 4
receptor (MC4R) deﬁciency is the commonest monogenic
form of obesity. Mutations in MC4R gene are noted in
about 6% of subjects with severe obesity of early onset
(before 10 years of age) [11]. Moreover, adults homozy-
gous for rs17782313 (CC) had 0.44 BMI units more in
comparison to carriers of other genotypes [12].
Based on well-assessed inﬂuence of above mentioned
SNPs on obesity development and the elevated frequency
of postmenopausal breast cancer in obese women, we
hypothesized that these polymorphic sites may be also
involved in carcinogenesis.
However, no signiﬁcant association between polymor-
phic sites rs9939609 and rs9930506 in FTO and rs17782313
in MC4R and risk of breast cancer was observed in the study
group.
In contrast, carriers of G allele in rs10146997 of NRXN3
gene had higher risk for breast cancer development
[OR = 0.66 (95% CI 0.44–0.99)] in comparison with other
genomic variants in this locus. NRXN3 and NRXN1 are
among the largest human genes, they encode neurexins—
polymorphic cell surface proteins expressed mainly in
neurons [13]. Three of the genes (NRXN1-3) utilize two
alternate promoters and include numerous alternatively
spliced exons to generate thousands of distinct mRNA
transcripts and protein isoforms [14]. Heard-Costa et al.
identiﬁed a SNP (rs10146997) as a novel locus in the
NRXN3 gene associated with waist circumference (WC)
They observed that mean waist circumference was higher
among G allele carriers in rs10146997 of NRXN3 gene, and
this variant was also associated with elevated BMI and the
risk of obesity [7]. NRXN3 has been previously implicated
in addictions (alcohol dependence, cocaine addiction, and
illegal substance abuse) [15]. However, up to date the
association between NRXN3 genotype and breast cancer
incidence has not been validated.
An additional analysis of possible impact of genotype on
the age of breast cancer onset revealed that the youngest
age at presentation of breast cancer had women who were
G allele carriers in rs10146997 of the NRXN3 gene, the
oldest age at onset—C allele carriage in rs177782313 of
the MC4R gene, but none of them achieved statistical
signiﬁcance.
In summary, inﬂuence of adipose tissue on cancer
development is extremely complex with poorly understood
role of its genetic background. Probably particular poly-
morphisms responsible for promoting obesity have a mild
inﬂuence on carcinogenesis. However, further functional
analyses are required to elucidate the role of genomic
variation in both developments of obesity and breast
cancer.
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